Kindbody Appoints Dean Morbeck, Ph.D., as First Chief Scientific Officer

·4 min read

Dr. Morbeck Brings More Than 25 Years of Fertility Experience Improving IVF Success Rates, Patient Experience and Building Research Teams

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Kindbody, the leading fertility and family-building company seeking to revolutionize the patient experience, today announced the appointment of Dean Morbeck, Ph.D., as the Company's Chief Scientific Officer. Dr. Morbeck, a leading researcher in the area of In Vitro Fertilization (IVF), brings more than 25 years of experience in the field. Dr. Morbeck will apply his scientific expertise and highly specialized areas of research to support Kindbody's full-service family-building service offering as the company continues its rapid expansion.

Dean Morbeck, Kindbody Chief Scientific Officer
Dean Morbeck, Kindbody Chief Scientific Officer

"I am delighted to join Kindbody and look forward to working with this amazing team as we seek to further improve the delivery of care to our patients," said Dr. Morbeck. "Kindbody is fully embracing technology and research as a means to improve outcomes and make IVF more effective, but what stands out to me the most is its all-encompassing emphasis on improving the patient experience, something I am very passionate about. I'm thrilled to be joining such an innovative organization that has the potential to transform the IVF experience for patients."

"We are thrilled to add an experienced scientist like Dean to help further our mission of using data-driven research to deliver exceptional care," said Annbeth Eschbach, President of Kindbody. "Dean has a wealth of experience in this field and is passionate about delivering the highest quality care to patients. We have no doubt that under his leadership, Kindbody will continue to provide outstanding results to our patients."

Under Dr. Morbeck's leadership, Kindbody will conduct research focused on making IVF more successful, ultimately leading to improved pregnancy rates. By leveraging the latest technology, including new medical devices and artificial intelligence (AI), and placing a heavy emphasis on scientific research, Dr. Morbeck and his team will focus on improving embryo culture quality control and embryo selection, factors that directly impact IVF success rates. This unique research capability further establishes Kindbody as a differentiated provider of the highest quality end-to-end care to patients seeking family building and fertility assistance.

Dr. Morbeck most recently served as the Scientific Director for Fertility Associates, New Zealand's leading provider of fertility diagnosis, support, and treatment, as well as an Honorary Lecturer in Obstetrics and Gynaecology at the University of Auckland and as an adjunct Associate Professor in the Department of Obstetrics and Gynecology at Monash University in Melbourne. Prior to his role at Fertility Associates, he was an Associate Professor of Obstetrics and Gynecology and Laboratory Medicine and Pathology at the Mayo Clinic, where he spent 10 years. Prior to that, he spent over 10 years as a laboratory director in private practice. He received his Ph.D. in physiology from North Carolina State University and completed his post-doc fellowship at the Mayo Clinic Graduate School of Biomedical Sciences. He also holds an MBA.

Dr. Morbeck's research focuses on in vitro stress during embryo culture, specifically, identifying sources of stress and developing improved methods for detection and prevention of factors that cause stress during preimplantation embryo culture. He has also conducted research to explore the benefits of time-lapse imaging for improving conditions and providing better embryo selection.

As an embryologist, academic and scientific consultant, Dr. Morbeck has been actively involved in all aspects of fertility care ranging from the patient experience and clinical procedures to improving the quality of the embryo culture environment and decision-making by embryologists. He is passionate about providing the highest quality care to patients experiencing infertility, and has authored numerous publications on quality control, media composition and laboratory KPIs.

Morbeck joins a team of other industry veterans at Kindbody, including Founder and CEO Gina Bartasi, a seasoned entrepreneur with 20+ years' experience in healthtech and the founder of Progyny, President Annbeth Eschbach, previously the Founder and CEO of Exhale Spa, Chief Medical Officer, Dr. Lynn Westphal, previously at Stanford Fertility, and Founding OB/GYN, Dr. Fahimeh Sasan, previously of Mount Sinai Health System in New York.

About Kindbody

Kindbody provides fertility, gynecology, and family-building services at over 300 locations around the country, including signature retail clinics, mobile clinics, and partner clinics. With a mission to deliver a more welcoming, inclusive experience for all, Kindbody leverages proprietary technology to enable high-touch care and superior outcomes at lower prices. Founded in 2018 by CEO Gina Bartasi, Kindbody has raised a total of $122 million in funding from leading investors including Perceptive Advisors, GV (formerly Google Ventures), RRE Capital, Claritas Health Ventures, Rock Springs Capital, NFP Ventures, and TQ Ventures. Its leadership team includes President, Annbeth Eschbach; Chief Financial Officer, Meredith Whitney; Chief Medical Officer, Dr. Lynn Westphal; Chief Business and Legal Officer; Shilpa Patel; Founding Physician, Dr. Fahimeh Sasan; Chief Scientific Officer, Dean Morbeck; Chief Commercial Officer, Cindy Gentry; and Chief Technology Officer, Richard Forsythe.

Amandalyn Jones


View original content to download multimedia:

SOURCE Kindbody

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting